New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease
Go back to New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease| AbbVie (NYSE: ABBV) | Delayed: 284.80 -4.28 (1.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $289.08 | 52 Week High | $68.12 | |||
| Open | $287.63 | 52 Week Low | $50.71 | |||
| Day High | $289.00 | P/E | 61.78 | |||
| Day Low | $282.15 | EPS | $4.61 | |||
| Volume | 4,394,198 | |||||



